129
Participants
Start Date
January 4, 2024
Primary Completion Date
August 5, 2024
Study Completion Date
September 18, 2024
ICP-488 Tablets
ICP-488 will be administered as tablet
ICP-488 Placebo
ICP-488 Placebo will be administered as tablet
Beijing Friendship Hospital, Capital Medical University, Beijing
China-Japan Friendship Hospital, Beijing
First Hospital of Jilin University, Changchun
Mei he kou central hospital, Meihekou
Shanghai Dermatology Hospital, Shanghai
Huashan Hospital Affiliated to Fudan University, Shanghai
Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of medical Sciences, Peking Union Medical College, Nanjing
Changzhou First People's Hospital, Changzhou
Lianyungang First People's Hospital, Lianyungang
Central Hospital affiliated to shandong first medical unversity, Jinan
Hangzhou First People's Hospital, Hangzhou
Zhejiang Provincial People's Hospital, Hangzhou
The First Hospital of Jiaxing, Jiaxing
The First Affiliated Hospital of Wenzhou Medical University, Wenzhou
The First Affiliated Hospital of Fujian Medical University, Fuzhou
The First Affiliated Hospital of Chongqing Medical University, Chongqing
Xiangya hospital central south university, Changsha
Wuhan University People's Hospital, Wuhan
Wuhan No.1 hospital, Wuhan
Shiyan City People's Hospital, Shiyan
Henan Provincial People's Hospital, Zhengzhou
Nanyang city first People's Hospital, Nanyang
Dermatology Hospital of Southern Medical University, Guangzhou
Guangdong Hospital of Traditional Chinese Medicine, Guangzhou
Affiliated Hospital of Guizhou Medical University, Guiyang
Chengdu Second People's Hospital, Chengdu
The First Affiliated Hospital of Kunming Medical University, Kunming
The Affiliated Hospital of Chengde Medical College, Chengde
The first hospital of hebei medical university, Shijiazhuang
The Second Affiliated Hospital of Hebei Medical University, Shijiazhuang
Affiliated Hospital of Inner Mongolia Medical University, Hohhot
Beijing InnoCare Pharma Tech Co., Ltd.
INDUSTRY